Innovation Pharmaceuticals Inc (IPIX)

[warrenthomas4001]

No. Unless our B data is total fabrication, there is zero justification to pivot away from C19. In fact, I would unequivocally allocate all our powder for C19. Here’s a reminder as to the FLIP SIDE of what our MAB competition brings to the table:
1) Low blood pressure
2) anaphylaxis
3) serious infections
4) Cancers
5) Serum sickness
6) Autoimmune thyroiditis
7) arterial and venous clots
8) congestive heart failure
9) bleeding
10) Interstitial lung disease
11) Hepatitis
12) Enterocolitis
13) Gastro intestinal perforation
14) Mucositis
15) stomatitis
16) Anemia
17) reduced white blood cell counts
18) Hypothyroidism
19) serious drug interactions

MABS aren’t all rainbows and puppy dogs. Brilacidin has what they don’t: An incomparable safety profile.